Related Experiment Video
Updated: Mar 2, 2026
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Common pitfalls in preclinical cancer target validation
1Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Abstract:
An alarming number of papers from laboratories nominating new cancer drug targets contain findings that cannot be reproduced by others or are simply not robust enough to justify drug discovery efforts. This problem probably has many causes, including an underappreciation of the danger of being misled by off-target effects when using pharmacological or genetic perturbants in complex biological assays. This danger is particularly acute when, as is often the case in cancer pharmacology, the biological phenotype being measured is a 'down' readout (such as decreased proliferation, decreased viability or decreased tumour growth) that could simply reflect a nonspecific loss of cellular fitness. These problems are compounded by multiple hypothesis testing, such as when candidate targets emerge from high-throughput screens that interrogate multiple targets in parallel, and by a publication and promotion system that preferentially rewards positive findings. In this Perspective, I outline some of the common pitfalls in preclinical cancer target identification and some potential approaches to mitigate them.
Insights
Many preclinical cancer drug target studies lack reproducibility due to off-target effects and biased reporting. This perspective highlights common pitfalls in target identification and suggests mitigation strategies for robust drug discovery.
Area of Science:
- Oncology
- Pharmacology
- Biomedical Research
Background:
- A significant portion of preclinical cancer research nominating drug targets yields irreproducible or non-robust findings.
- Underappreciation of off-target effects in pharmacological or genetic assays contributes to unreliable results.
- Measuring 'down' readouts like decreased proliferation can mask nonspecific cellular fitness loss, complicating target validation.
Purpose of the Study:
- To identify common pitfalls in preclinical cancer target identification.
- To propose methods for mitigating these challenges in drug discovery efforts.
- To improve the reliability and robustness of findings in cancer target nomination.
Main Methods:
- Analysis of common issues in preclinical cancer research.
- Discussion of off-target effects in biological assays.
- Review of challenges in high-throughput screening and data interpretation.
Main Results:
- Identified pitfalls include misinterpretation of off-target effects and reliance on 'down' readouts.
- Compounding factors such as multiple hypothesis testing and publication bias were noted.
- The need for more rigorous validation of candidate cancer drug targets is emphasized.
Conclusions:
- Preclinical cancer target identification faces significant reproducibility challenges.
- Addressing off-target effects and improving assay design are crucial.
- Mitigation strategies are necessary to ensure robust drug discovery pipelines.
More Related Videos
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:28Preclinical Development: Overview